Abstract
Obstructive sleep apnea (OSA) is a common sleep disorder affecting high proportion of the population. This disorder is associated with an increase in the oxidative stress and cardiovascular disease. Paraoxonase (PON) is a lipolactonase enzyme removing toxic lipids and decreasing lipoprotein oxidation. The present study was conducted to reassess possible alternation of PON activities in OSA patients. Studies measured PON activities in OSA were searched in PubMed, Scopus, EMBASE, Web of Science databases, and Cochrane Library from January 1990 to February 2019. Screening of the studies was performed by two authors independently according to title, abstract, and full text. Quality of studies was assessed by Newcastle-Ottawa Quality Assessment Scale, and random-effect model was used for evaluating the effect of OSA on PON activities. A total of 97 records were found in searching, 39 duplicated records were removed, and 5 studies for PON activity and 2 studies for aryl-esterase (ARE) activity were included in the meta-analysis. Pooled analysis showed no significant difference in terms of PON activity between OSA and control groups (p = 0.434). Similarly, ARE demonstrated no significant difference between OSA and control groups (p = 0.515). Subgroup meta-analysis according to age, BMI, AHI, and diagnosis criteria demonstrated no significant difference between two groups. The results of this study indicated no association between OSA and PON activities as an antioxidant enzyme. However, a relatively low number of studies limited us to conclude a definite conclusion; therefore, more studies are needed in this regard.
Similar content being viewed by others
References
Lurie A. Obstructive sleep apnea in adults: epidemiology, clinical presentation, and treatment options. Adv Cardiol. 2011;46:1–42. https://doi.org/10.1159/000327660.
Khazaie H, Najafi F, Rezaie L, Tahmasian M, Sepehry AA, Herth FJ. Prevalence of symptoms and risk of obstructive sleep apnea syndrome in the general population. Arch Iran Med. 2011;14(5):335–8.
Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47–112. https://doi.org/10.1152/physrev.00043.2008.
Shahveisi K, Jalali A, Moloudi MR, Moradi S, Maroufi A, Khazaie H. Sleep architecture in patients with primary snoring and obstructive sleep apnea. Basic Clin Neurosci. 2018;9(2):147–56. https://doi.org/10.29252/NIRP.BCN.9.2.147.
Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011;140(2):534–42. https://doi.org/10.1378/chest.10-2223.
Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Prim. 2015;1:15015. https://doi.org/10.1038/nrdp.2015.15.
Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453–R62. https://doi.org/10.1016/j.cub.2014.03.034.
Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, et al. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front Physiol. 2017;8:600. https://doi.org/10.3389/fphys.2017.00600.
Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl). 2017;95(11):1153–65. https://doi.org/10.1007/s00109-017-1575-8.
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9–19. https://doi.org/10.1097/WOX.0b013e3182439613.
Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567(1):12–21. https://doi.org/10.1016/j.gene.2015.04.088.
Mahrooz A. Pharmacological interactions of paraoxonase 1 (PON1): a HDL-bound antiatherogenic enzyme. Curr Clin Pharmacol. 2016;11(4):259–64.
Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012;4(11):523–32. https://doi.org/10.4103/1947-2714.103310.
Lira AB, de Sousa Rodrigues CF. Evaluation of oxidative stress markers in obstructive sleep apnea syndrome and additional antioxidant therapy: a review article. Sleep Breath. 2016;20(4):1155–60. https://doi.org/10.1007/s11325-016-1367-3.
Eisele HJ, Markart P, Schulz R. Obstructive sleep apnea, oxidative stress, and cardiovascular disease: evidence from human studies. Oxidative Med Cell Longev. 2015;2015:608438. https://doi.org/10.1155/2015/608438.
Okur HK, Pelin Z, Yuksel M, Yosunkaya S. Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia. Sleep Breath. 2013;17(1):365–71. https://doi.org/10.1007/s11325-012-0703-5.
Andaku DK, D'Almeida V, Carneiro G, Hix S, Tufik S, Togeiro SM. Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: a cross-sectional study. Respir Res. 2015;16(1):3. https://doi.org/10.1186/s12931-015-0166-x.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.
Vatansever E, Surmen-Gur E, Ursavas A, Karadag M. Obstructive sleep apnea causes oxidative damage to plasma lipids and proteins and decreases adiponectin levels. Sleep Breath. 2011;15(3):275–82. https://doi.org/10.1007/s11325-010-0378-8.
Andaku DK, D'Almeida V, Carneiro G, Hix S, Tufik S, Togeiro SM. Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: a cross-sectional study. Respir Res. 2015;16(1). https://doi.org/10.1186/s12931-015-0166-x.
Kim J, Lee S, In K, Kim J, You S, Kang K, et al. Increase in serum haptoglobin and apolipoprotein M in patients with obstructive sleep apnoea. J Sleep Res. 2009;18(3):313–20. https://doi.org/10.1111/j.1365-2869.2008.00725.x.
Baysal E, Taysi S, Aksoy N, Uyar M, Celenk F, Karatas ZA, et al. Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS). Eur Rev Med Pharmacol Sci. 2012;16(6):770–4.
Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med. 2002;165(7):934–9. https://doi.org/10.1164/ajrccm.165.7.2104126.
Asker S, Asker M, Sarikaya E, Sunnetcioglu A, Aslan M, Demir H. Oxidative stress parameters and their correlation with clinical, metabolic and polysomnographic parameters in severe obstructive sleep apnea syndrome. Int J Clin Exp Med. 2015;8(7):11449–55.
Kota SK, Meher LK, Kota SK, Jammula S, Krishna SVS, Modi KD. Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol Metab. 2013;17(3):402–12. https://doi.org/10.4103/2230-8210.111618.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed Consent
No informed consent is needed for a systematic review.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Medicine
Rights and permissions
About this article
Cite this article
Fadaei, R., Safari-Faramani, R., Rezaei, M. et al. Paraoxonase Activity in Patients with Obstructive Sleep Apnea: a Systematic Review and Meta-analysis. SN Compr. Clin. Med. 2, 25–31 (2020). https://doi.org/10.1007/s42399-019-00202-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42399-019-00202-1